Contraindications
- Severe aortic stenosis
- Hypersensitivity (caution with prior dihydropyridine allergy)
Dosing: Adult
- Hypertension: 2 mg once daily in the morning; increase to 4 mg and then 6 mg after 3 to 4 weeks on each dose if needed
Dosing: Altered kidney function
Lacidipine is a dihydropyridine calcium-channel blocker metabolized by the liver (CYP3A4) and excreted mainly in feces as metabolites. The Dutch label needs no kidney dose adjustment because it is not renally excreted. It has no US FDA label.
Kidney function measure: SmPC sets no kidney adjustment; bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 2 mg once daily in the morning; increase to 4 mg, then 6 mg, after at least 3 to 4 weeks on each dose (SmPC).
- CrCl 30–59 mL/min
- No dose adjustment: lacidipine is not excreted by the kidneys (SmPC).
- CrCl 15–29 mL/min
- No dose adjustment: lacidipine is not excreted by the kidneys (SmPC).
- CrCl <15 mL/min (not on dialysis)
- No dose adjustment: lacidipine is not excreted by the kidneys (SmPC).
- Hemodialysis (intermittent)
- No kidney adjustment (not renally excreted); no dialysis data in the SmPC. Highly protein-bound, so dialysis removal is unlikely.
- Peritoneal dialysis
- No kidney adjustment; no PD data.
- CRRT
- No data.
- Dialyzable? Not stated (over 95% protein-bound).
- Monitoring Blood pressure; edema; caution with conduction disease, QT prolongation and reduced cardiac reserve; avoid grapefruit (SmPC 4.4, 4.5).
Children (kidney dosing)
- eGFR ≥60
- Not established in children; kidney dosing not applicable.
- eGFR 30–59
- Not established in children; kidney dosing not applicable.
- eGFR 15–29
- Not established in children; kidney dosing not applicable.
- eGFR <15 (not on dialysis)
- Not established in children; kidney dosing not applicable.
- Hemodialysis (intermittent)
- Not established in children; kidney dosing not applicable.
- Peritoneal dialysis
- Not established in children; kidney dosing not applicable.
- CRRT
- Not established in children; kidney dosing not applicable.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: CBG-MEB (Netherlands) product information (December 22, 2022). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- Not recommended under 18 years (SmPC).
- Usual dose
- Not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 2 mg, 4 mg, 6 mg
- Tablet: 6 mg
Registered products in the Philippines
6 products registered with the Food and Drug Administration (FDA) Philippines list Lacidipine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Lacipidine (1 product). Products registered under these spellings are included in the table and marked.
All registered products6
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
CalcipineLacidipine | 4mg Film-Coated TabletAlu/Alu Blister Pack x 8's Box of 24's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-9545 | Jan 29, 2029 | |
LaciblocLacidipine | 4 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | LLOYD LABORATORIES INC.Philippines | TGP-PHARMA INC.Trader: EUROHEALTH CARE EXPONENTS,INC. | DRP-9545-01 | Jan 29, 2029 | |
LaciblocLacidipine | 6 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Ultramed Pharma, Inc. | DR-XY38934 | Jan 11, 2031 | |
2 mg Film-Coated TabletChild-Resistant Aluminum Foil Blister Pack x 7's (Box of 28's) | Rx | GLAXO WELLCOME S.A.Spain | Importer: GLAXOSMITHKLINE PHILIPPINES, INC. | DR-XY16826 | Aug 18, 2028 | ||
LacipilLacidipine | 6 mg TabletChild-Resistant Aluminum Foil Blister Pack x 7's (Box of 28's) | RxVAT-exempt | GLAXO WELLCOME S.A.Spain | GLAXOSMITHKLINE PHILIPPINES, INC. | DR-XY29222 | Dec 4, 2028 | |
UnbrandedLacidipine | 6 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | — | DRP-10490 | Oct 5, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Strong CYP3A4 inhibitors or inducers (itraconazole, rifampicin), cimetidine | Adjust or monitor | Altered lacidipine levels. | Monitor blood pressure. |
| Grapefruit juice | Avoid | Altered bioavailability. | Avoid. |
| Other antihypertensives, alcohol | Minor | Additive blood-pressure lowering. | Monitor. |
| Corticosteroids, tetracosactide | Minor | Less antihypertensive effect. | Monitor. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Headache, dizziness
- Palpitations, tachycardia, flushing
- Edema, asthenia
- Nausea, rash, polyuria
- Raised alkaline phosphatase
Serious
- Worsening angina (caution in unstable angina and after recent myocardial infarction)
Monitoring parameters
- Blood pressure; edema; caution with conduction disease, QT prolongation and reduced cardiac reserve; avoid grapefruit (SmPC 4.4, 4.5). Kidney
- Blood pressure
- Edema
Pharmacokinetics
Key PK parameters
| Bioavailability | About 10% (high first pass) |
|---|---|
| Time to peak | 30 to 150 minutes |
| Half-life | 13 to 19 hours (steady state) |
| Protein binding | Over 95% |
| Metabolism (CYP, transporters) | Hepatic, mainly CYP3A4 (inactive metabolites) |
| Renal excretion kidney | About 70% as metabolites in feces; remainder in urine (not as parent) |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Medicines Evaluation Board (CBG-MEB), Netherlands. Lacidipine Teva 2 mg/4 mg film-coated tablets SmPC (RVG 105980) [CBG-MEB (Netherlands) product information, December 22, 2022; no US FDA label]. https://www.geneesmiddeleninformatiebank.nl/smpc/h105980_smpc.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Teva Nederland BV. (2022). Lacidipine 2 mg and 4 mg Teva, film-coated tablets (RVG 105980/105981) [Summary of product characteristics; text dated December 22, 2022]. College ter Beoordeling van Geneesmiddelen (Medicines Evaluation Board), Netherlands. https://www.geneesmiddeleninformatiebank.nl/smpc/h105980_smpc.pdf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .